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Background: There is only retrospective and very limited data for the long term prognosis of Takayasu's Arteritis (TAK), a rare large-vessel vasculitis. In this study, we aimed to present the preliminary results of a Takayasu Inception Cohort settled for long term, prospective follow-up of only newly-diagnosed patients with TAK. Methods: Patients fullfilling the American College of Rheumatology 1990 criteria for TAK and diagnosed in the last 12 months were included to the study. Patients' data were recorded in an electronic database of an international "Takayasu's Arteritis Registry" requiring baseline and at least annual visits. Data is compared with an historical Turkish cohort previously published (Bıçakçıgil, et al, 2009 classification, 59.2% of the study group had type I and only 17.2% had type V disease. When we compared our results to our retrospective cohort (previously published by Turkish Takayasu Arteritis Study Group), constitutional symptoms (72.2% vs 66%) and limb claudication (62.3% vs 48%) were observed to be more frequent, whereas pulselessness (35.6% vs 88%) was less in the inception cohort. (Table 1 ) Carotidynia was present only in the inception cohort. Similarly, mucocutaneous symptoms also seem to be a feature of newly-diagnosed disease (26.4% vs 8.8%). Regarding comorbidities at diagnosis, the rate of dyslipidemia was 22%, diabetes mellitus 6%, smoking 28.5% and obesity (BMI>30) 15.8% among TAK patients. All patients were given oral corticosteroid (CS) therapy (0.5-1 mg/kg) at diagnosis, 10 patients (7.8%) also having CS pulses. In addition to CSs, 55 patients (43%) were given methotrexate, 14 patients (11%) azathioprine and 5 (4%) cyclophosphomide at disease-onset. Conclusions: Our results suggest that, in an inception cohort, signs and symptoms of "systemic inflammation" is more prominent in newly-diagnosed TAK patients, whereas vascular extent and damage accumulates during the disease course. The long term follow-up of our inception cohort will better show the actual course and predictors of prognosis in TAK. Background: Colour Doppler sonography (CDS) is an emerging diagnostic tool for giant cell arteritis (GCA), however, its use in routine practice is still not widespread. Objectives: To develop a protocol using CDS and explore its value in the routine care of patients with GCA. Methods: We developed a structured scanning protocol for CDS of temporal and axillary arteries (total of 8 anatomical sites scanned per patient) based on previously published methods. We tested the protocol on consecutive patients referred to a single rheumatology centre, with suspected or established GCA, between July 2014 and September 2016. We defined a positive scan by the presence of halo in at least one branch of a temporal artery (TA) or one axillary artery (AX). We report data from the first 293 consecutively scanned cases. Results: We assessed 293 patients (mean age 72±10, female/male 196/97), of whom 118 had clinically confirmed GCA. Amongst new referrals with confirmed diagnosis of GCA, 44% had a positive scan; two patients with a positive scan did not have GCA. 82% of new referrals patients showed exclusive TA involvement, 25% concomitant AX, and 4% exclusive AX involvement. High-dose glucocorticoid therapy had already been started in 78% of these patients for an average of 17±33 days. Amongst this group, the sensitivity of CDS was 46% (95% IC 37%>55%), specificity 98% (95% CI 93%>99.8%), positive predictive value 96% (88%>99.6%), and negative predictive value 60% (95% IC 52%>68%). During the period of observation, the rate of temporal artery biopsies (TAB) decreased significantly from 42% to 25% (p=0.002). During follow up, CDS was positive in 21% of 89 routine scans in asymptomatic individuals, compared to 58% in patients with confirmed clinical flares (45% of whom had negative inflammatory markers). Over time, the number of halos per patient reduced; only new or flaring patients showed a halo in >4 sites. Halo size at the TA did not change significantly (average thickness 0.6±0.1 mm), however, the size of AX artery halos significantly reduced from first referral (1.6±0.4 mm) to follow up (1.4±0.2, p=0.01) or during subsequent flares (1.4±0.2, p=0.02).
Conclusions:
We have developed and tested a standardised methodology for CDS evaluation of GCA. CDS provides a high positive predictive value for a diagnosis of GCA in unselected patients from routine clinical practice, although prior high dose glucocorticoid therapy is likely to reduce its sensitivity. CDS allows for a significant reduction of TAB. We explored the role of CDS to detect disease flares and demonstrated a significant reduction in the extent of abnormalities, and of the size of halo of the AX arteries during follow up or flares. These findings could have a significant impact on the management of patients with suspected and confirmed GCA. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4063 
